R
Richard A. Messmann
Researcher at Novartis
Publications - 32
Citations - 1882
Richard A. Messmann is an academic researcher from Novartis. The author has contributed to research in topics: Prostate cancer & Pharmacokinetics. The author has an hindex of 15, co-authored 29 publications receiving 1107 citations. Previous affiliations of Richard A. Messmann include University of Texas Southwestern Medical Center & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Oliver Sartor,Johann S. de Bono,Kim N. Chi,Karim Fizazi,Ken Herrmann,Kambiz Rahbar,Scott T. Tagawa,Luke T. Nordquist,Nitin Vaishampayan,Ghassan El-Haddad,Chandler H Park,Tomasz M. Beer,Alison Armour,Wendy J Pérez-Contreras,Michelle DeSilvio,Euloge Kpamegan,Germo Gericke,Richard A. Messmann,Michael J. Morris,Bernd J. Krause,Vision Investigators +20 more
TL;DR: In this paper, Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer and remains fatal despite recent advances in medical technology.
Journal ArticleDOI
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
Edward A. Sausville,Susan G. Arbuck,Richard A. Messmann,Donna Headlee,Kenneth S. Bauer,Richard Lush,Anthony J. Murgo,William D. Figg,Tyler Lahusen,Susan Jaken,Xiu-xian Jing,Michel Roberge,Eiichi Fuse,Takashi Kuwabara,Adrian M. Senderowicz +14 more
TL;DR: Preliminary evidence suggests UCN-01 modulation of both PKC substrate phosphorylation and the DNA damage-related G(2) checkpoint may be responsible for disease stability in refractory neoplasms.
Journal ArticleDOI
Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms
Antoinette R. Tan,Donna Headlee,Richard A. Messmann,Edward A. Sausville,Susan G. Arbuck,Anthony J. Murgo,Giovanni Melillo,Suoping Zhai,William D. Figg,Sandra M. Swain,Adrian M. Senderowicz +10 more
TL;DR: Flavopiridol as a daily 1-hour infusion can be safely administered and can achieve concentrations in the micromolar range, sufficient to inhibit cyclin-dependent kinases in preclinical models.
Journal Article
A Phase I Study of Combination Therapy with Immunotoxins IgG-HD37-Deglycosylated Ricin A Chain (dgA) and IgG-RFB4-dgA (Combotox) in Patients with Refractory CD19(+), CD22(+) B Cell Lymphoma
Richard A. Messmann,Ellen S. Vitetta,Donna Headlee,Adrian M. Senderowicz,William D. Figg,John Schindler,Dennis F. Michiel,S P Creekmore,Seth M. Steinberg,David R. Kohler,Elaine S. Jaffe,Maryalice Stetler-Stevenson,Huachun Chen,Victor Ghetie,Edward A. Sausville +14 more
TL;DR: It is found that non-aggregate-forming formulations for these ITs should be pursued prior to future clinical trials, and the potential to aggregate does suggest one possible basis for problems in the clinical experience with HD37-dgA.
Journal ArticleDOI
Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors
Patricia M. LoRusso,Martin J. Edelman,Susan L. Bever,Karen Forman,M. J. Pilat,Mary F. Quinn,Jing Li,Elisabeth I. Heath,Lisa Malburg,Patrick J. Klein,Christopher P. Leamon,Richard A. Messmann,Edward A. Sausville +12 more
TL;DR: EC145 administered by bolus injection or as a 1-hour infusion at a dose of 2.5 mg has an acceptable safety profile in patients with advanced cancer and phase II studies of EC145 have been initiated in Patients with advanced epithelial ovarian cancer and non-small-cell lung cancer.